HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine

Silvia Baroncelli1, Clementina Maria Galluzzo1, Giuseppe Liotta2, Mauro Andreotti1, Stefano Orlando2, Fausto Ciccacci3, Robert Mphwere4, Richard Luhanga4, Jean Baptiste Sagno4, Roberta Amici1, Maria Cristina Marazzi5 and Marina Giuliano1

Abstract

Background: In sub-Saharan African countries Epstein Barr virus (EBV) infection occurs in early childhood. We aim to investigate the factors associated with EBV acquisition and the impact of EBV infection on the humoral response to HBV vaccination in infants born from HIV-positive, antiretroviral-treated mothers in Malawi.

Methods: A total of 149 HIV-exposed infants were included in this longitudinal study. EBV anti-VCA IgG were measured using an ELISA assay. The EBV seroconversion was correlated with the maternal viro-immunological conditions, with infant growth and immunological vulnerability, and with the humoral response to the HBV vaccine.

Results: No infant was EBV-positive at 6 months (n. 52 tested). More than a third of infants (49/115 or 42.6 %) on study beyond 6 months seroconverted at 12 months. At 24 months, out of 66 tested infants, only 13 remained EBV-uninfected, while 53 (80.3 %) acquired EBV infection, rising the total proportion of EBV seroconversion to 88.7 % (102/115 infants). EBV seroconversion was significantly associated with a low maternal educational status but had no impact on infant growth or vulnerability to infections. Reduced HBsAb levels and accelerated waning of antibodies were associated with early EBV seroconversion.

Conclusions: We found a heterogeneous timing of acquisition of EBV with the majority of infants born from HIV + mothers acquiring infection after 6 months. Anti-HBs levels were lower and appeared to wane faster in infants acquiring EBV infection.

Keywords: HIV exposed uninfected infants, EBV acquisition, response to HBV vaccine, Malawi

Background

The Epstein-Barr virus (EBV) is ubiquitous in human populations, it establishes a lifelong latency, with intermittent reactivation, and generally, limited clinical symptoms. In low-medium income settings, the peak of seroconversion occurs in the early years of life [1], whereas in developed countries the infection follows a bimodal distribution: infection acquisition can occur during the first year of life or can be delayed until adolescence [2]. EBV is a B-lymphotropic virus, associated with lymphoproliferative disorders including several important lymphomas [3, 4]. Soon after the infection, EBV acts reprogramming biological processes and pathways of B cells [5]. In children living in sub-Saharan regions, endemic to malaria and HIV (both linked to immune system dysfunctions), EBV infection can trigger substantial changes in the biology of the entire host.
B-cell compartment. The interaction between EBV infection and malaria is well recognized in the development of Burkitt lymphoma, one of the most prevalent childhood cancer in equatorial Africa [6]. On the other hand, early EBV infection in HIV-exposed children can concur in determining immune system dysfunctions; exploratory studies have indicated that early infection with EBV in infants is associated with reduced antibody responses to polysaccharides and measles vaccines [7], while others have shown that EBV latency can accelerate the decay of immune response to measles and rubella vaccines [8]. Limited is the information on the impact of early EBV infection on the magnitude and persistence of immune response to Hepatitis B (HBV) vaccination. Hepatitis B is highly prevalent in Malawi: in the general population HBsAg seroprevalence is estimated at about 7.9% [9], and a similar rate has been observed in the HIV-positive population [10]. HBV vaccination is provided in Malawi as a component of a pentavalent vaccine preparation (scheduled at 6, 10, and 14 weeks of life), and the coverage of the 3-dose HBV vaccine is estimated to be around 95% [11]. Nevertheless, the HBsAg prevalence in children (<5 years) is estimated at around 1.5% [9]. The vaccination schedule does not include the child birth dose.

In the last decade, the number of HIV-exposed but uninfected (HEU) infants has increased constantly; in Malawi, in 2019 their prevalence exceeded 7% of the general child population, accounting for more than 600,000 children [12]. HEU infants show generalized immune system disorders leading to higher vulnerability to infections [13], impaired response to vaccinations (reviewed in 14), and a higher rate of mortality [15] compared to their unexposed counterparts. In this context, (of an immune vulnerable population) it is relevant to determine the rate and the timing of EBV infection, which could affect the maturation and the functions of the immune system over the life course.

In this study we evaluated EBV infection in a cohort of Malawian HEU infants with the following objectives: (a) to identify the potential factors associated with EBV infection acquisition in infants at 1 and 2 years of age, (b) to determine the possible impact of EBV infection on infants growth and vulnerability to infections and (c) to explore the impact of EBV infection on the magnitude of the humoral immune response following HBV vaccination and the persistence of protective titres over time.

Materials and methods

Study design

This sub-study included 149 infants, enrolled in a larger observational study that took place in Malawi between 2008 and 2011 to assess the safety and pharmacokinetics of maternal antiretroviral therapy administration during breastfeeding (Safe Milk for African Children[SMAC] study, [16]. In the study, treatment-naive HIV-infected women started antiretroviral treatment (ART) during pregnancy and continued it until 6 months postpartum, or indefinitely if the baseline CD4+ count was less than 350/mm³. Women were instructed to exclusively breastfeed for up to 6 months. After delivery, the mothers and their infants were monthly visited for clinical and laboratory assessment for up to 24 months.

The longitudinal sub-study was conducted on a total of 115 infants with complete follow-up and available plasma/serum samples collected at 12 and 24 months.

To determine very early EBV acquisition, additional 52 infants were tested for EBV-IgG at 6 months of age. Eighteen of the 52 infants were also included in the longitudinal study (available samples at 12 and 24 months), while 34 had only the 6-month sample.

Clinical assessments

Monthly clinic visits, scheduled as part of the cohort study, were performed during 24 months of follow-up. Physical examination was performed on mothers and infants and clinical data were recorded. Gastrointestinal and respiratory infections, and malaria, based on mothers’ reported symptoms, were diagnosed by clinical judgment following guidelines indication [17, 18].

Laboratory assays

Cytomegalovirus (CMV) infection in infants was diagnosed by anti-CMV IgM antibody determination (at 1 month of age) or by real-time PCR for DNA (Enzygnost CMV IgM and kPCR PLX® Cytomegalovirus (CMV) DNA Assay, Siemens Healthcare, Erlangen, Germany), at either 6 or 12 months of age, as already described [19].

Levels of antibodies elicited by HBV vaccine, scheduled at 6, 10, and 14 weeks of life, were determined by IgG anti-HBs assay (Enzygnost anti-HBs, Siemens Healthcare, Erlangen, Germany). According to previous studies, anti-HBs levels ≥ 10 mIU/ml were considered protective [20]. The maintenance of an adequate immune response to HBV was analyzed by measuring anti-HBs titres over time. The persistency of HBs titres was determined by their changes between 12 and 24 months; we arbitrarily categorized 4 types of dynamic responses to vaccine: (1) maintenance or increase of HBs IgG levels over 100 mIU/ml; (2) stable HBs IgG levels between >10<100 mIU/ml; (3) clinically relevant decrease (>50%) of HBs IgG levels (4) poor response to HBV vaccination (HBs IgG<10 mIU/ml at both time points).

Infant anthropometry variables were undertaken using methods already described [21]. Height-for-age (HAZ), weight-for-age (WAZ), weight-for-height (WHZ), and body-mass-index-for-age (BAZ) were calculated based...
on WHO references standard using WHO Anthro version 3.2.2 [22], using the internationally recognized z-scores and thresholds [23].

**EBV serology**
Antibodies for viral capsid antigen VCA-immunoglobulin G (EBV VCA-IgG ELISA MyBioSource Inc, Southern California, San Diego USA) were measured using 10 μl of serum. The procedure was performed according to the manufacturer’s instructions. For each calibrator, negative and positive controls the mean of duplicate readings was used: only if the coefficient of variation for each duplicate was less than 15% the test was considered valid. The OD was read at 450 nm within 15 min using an ELISA reader. The Ab Index of each determination was calculated by dividing the OD value of each sample by the cut-off (Calibrator OD × Calibrator Factor). The samples were considered EBV-positive when the Ab Index was greater than the cut-off value.

**Statistical analysis**
The SPSS software, version 26 (IBM, Somers, NY, USA) was used for statistical analyses. Results are presented as medians with interquartile range (IQR) and percentages. Geometric mean titre was used for anti-HBs. Differences between groups were evaluated using the χ² test or the Fisher’s exact test when appropriate for categorical variables, and by the Mann-Whitney U test for quantitative variables. The Wilcoxon test was used to detect longitudinal differences. Spearman’s correlation coefficient was used to evaluate correlations between quantitative variables. A linear regression analysis was performed to evaluate the determinants of EBV acquisition at Month 12, controlling for potential confounding factors (maternal age, viral load, CD4+ cell count, WHO stage, educational levels). Differences were considered statistically significant when P < 0.05.

**Results**

**Patient characteristics**
At enrollment, before antiretroviral treatment (ART), women had a median viral load of 4.1 HIV-RNA log Copies/ml (IQR: 3.3–4.6) and 338.5 CD4+ cell/µl (203.8–469.3). Based on their CD4+ cell count, women were introduced to antiretroviral therapy (a combination of stavudine (d4T), lamivudine (3TC), nevirapine (NVP), if baseline CD4+ count was < 350/mm³; or zidovudine (AZT), 3TC and NVP if baseline CD4+ count was > 350/mm³). During pregnancy, women received a median of 10 weeks (IQR: 7.0–13.0) of ART. At the time of delivery, most of the women had viremia levels below 1000 HIV-RNA copies/ml. Socioeconomic status was determined by educational status (64.3%: no school or primary; 35.7% secondary), occupation status (unemployed: 60.9%), and presence or absence of electricity at home (no electricity: 78.3%).

Most infants (97.4%) were born by vaginal delivery. The median weight within 15 days from delivery was 3.2 Kg (IQR: 2.78–3.50). The male/female ratio was 54/61 (48/52%).

**Anti-VCA IgG longitudinal study**
A total of 52 infants were tested for anti-VCA IgG at 6 months. 45/52 (86.5%) were negative to the IgG anti-VCA IgG test, and 7 infants were EBV positive. All 7 infants were subsequently re-tested and were negative for anti-VCA IgG, indicating maternal origin for these antibodies at 6 months.

At month 12, 49 out of 115 infants (42.6%) were IgG anti-VCA positive. Fifty-three of the remaining 66 seronegative infants (80.3%), developed an immune response against EBV in the following 12 months, as showed by the presence of IgG anti-VCA. Overall, at month 24 most infants (102/115, 88.7%) had antibodies against EBV, and only 13 (11.3%) were EBV-negative.

**Maternal and infant factors influencing EBV infection acquisition**
In the first 12 months, EBV infection acquisition in infants was not associated with maternal HIV parameters (WHO stage, p = 0.423, viral load, p = 0.779 CD4+ cell count, p = 0.655), nor with the duration (p = 1.000) or the type of regimen (p = 0.850) of antiretroviral treatment (Table 1), while it was significantly associated with lower socioeconomic conditions: 77.6% of the mothers of infants who acquired EBV had poor educational level (vs. 54.5% of the infants not EBV-infected at 12 months p = 0.018). In a linear regression analysis, adjusted for potentially confounding maternal variables (age, viro-immunological parameters, and ART duration), poor educational levels remained a significant determinant of EBV acquisition (p = 0.011).

A high percentage of infants (37 of the 55 infants tested) acquired CMV infection during the first 12 months of life. The CMV infection occurred in 12/20 (60.0%) infants EBV+ and in 25/35 (71.4%) EBV− infants (p = 0.551, Table 1).

Infants’ birth weight, gender, and body mass index at 1, 6, and 12 months were not associated with an increased infants’ vulnerability to EBV infection at 12 months. EBV infection was observed in 1 of the two cases of pediatric HIV (HIV infection at 3 months), while the other (HIV+ infant (HIV infection at 12 months) remained EBV-negative during the study.
At 24 months the 13 infants remaining EBV-seronegative did not differ from those who acquired the infection; no differences were found in male/female ratio, growing rate (BMI and malnutrition indices at different time points, data not shown), the occurrence of other infections. During the 24 months of follow-up, 67.8% of the infants experienced at least one of the most common infections reported in Malawi: gastroenteritis, respiratory infections, and malaria. Based on the timing of EBV infection acquisition, the prevalence of cumulative low respiratory tract infections (18.4.0%, 28.3 and 15.4%, p = 0.392), malaria (40.8, 43.4 and 69.2%, p = 0.175) and gastroenterological events (34.7, 34.0 and 53.8%, p = 0.925) did not differ between the infants that EBV-seroconverted at 12 months (n = 49), within 24 months (n = 53) and those remaining seronegative (n = 13) during the study.

The magnitude and the persistence of the immune response to HBV vaccination were measured in all infants by determining anti-HBs IgG titres. At 12 months anti-HBs concentrations did not differ in infants according to the presence of EBV infection (geometric mean EBV+: 101.7 ± 51.6 vs. EBV−: 138.4 ± 42.9 mIU/ml, p = 0.777). Anti-HBs IgG titres over 10 mIU/ml (considered protective) were observed in 87.2% of EBV+ and 92.2% of EBV− infants, p = 0.523.

At month 24 the anti-HBs titres were 124.8 ± 71.4 mIU/ml in EBV-seronegative infants, and 41.4 ± 45.4 mIU/ml and 49.4 ± 35.8 mIU/ml in infants who seroconverted at 12 months or at 24 months, respectively (intergroup difference p = 0.008, Fig. 1).

Generally, the longitudinal trend in anti-HBs IgG titres showed a decline in all infants which became statistically significant only in the EBV seropositive infants, independently by the time of seroconversion (EBV-free: p = 0.070; EBV+ month 12: p = 0.004, EBV+ month 24: p < 0.0001, Fig. 1). A more detailed description of the evolution of anti-HBs levels during 12–24 months is reported in Table 2. The proportion of infants with high (> 100 IU/ml) antibody levels is underrepresented (15/52, 28.8%) in infants that became infected during the second year of life, compared to infants with early infection (21/45, 46.7%) and EBV-negative infants (7/11, 63.6%). Importantly, more than 50% (27/52) of infants with EBV acquisition during the second year of life experienced a relevant decay of vaccine-specific anti-HBs Ab. At month

Table 1 Analysis of potential maternal factors influencing EBV infection in infants during the first 12 months of life and infants characteristics

|                        | EBV+ infants (n = 49) | EBV− infants (n = 66) | P value |
|------------------------|-----------------------|-----------------------|---------|
| Maternal age (years)   | 28.0 (23.0–30.5)      | 26.5 (24.0–31.3)      | 0.847   |
| Weight (kg)            | 59.5 (54.9–66.8)      | 55.5 (51.2–65.4)      | 0.049   |
| Hemoglobin (g/l)       | 10.3 (9.4–11.3)       | 10.3 (9.1–11.4)       | 0.832   |
| HBV infection (n,%)    | 3 (6.1%)              | 4 (6.1%)              | 1.000   |
| CD4+ count (cells/µl)  | 390 (218–490)         | 336 (204–468)         | 0.655   |
| HIV-RNA (log copies/ml)| 4.08 (3.26–4.68)      | 4.10 (3.28–4.60)      | 0.779   |
| WHO stage (I/II/III–IV)| 77.6/10.2/12.2        | 77.3/19.7/3.0         | 0.423   |
| ART duration in pregnancy (weeks)| 10 (7.0–13.0) | 10 (6.0–13.3) | 1.000   |
| ART regimen: (n, %)    | d4T-3TC-NVP 26 (53.1%) | 37 (56.1%) | 0.850   |
|                       | AZT-3TC-NVP 23 (46.9%) | 29 (43.9%) |          |
| Unemployment (n, %)    | 32 (65.3%)            | 38 (57.6%)            | 0.444   |
| Low educational level (n, %) | 38 (77.6%) | 36 (54.5%) | 0.018   |
| No electricity at home (n, %) | 41 (83.7%) | 49 (74.2%) | 0.260   |
| Vaginal delivery (n, %) | 47 (97.9)            | 64 (97)               | 1.000   |
| Infants weight at birth (Kg)a | 3.2 (2.8–3.5) | 3.2 (2.6–3.5) | 0.562   |
| Male/female ratio (%)  | 49/51                 | 45.5/54.5             | 0.850   |
| HIV positive infants (n, %) | 1 (2.0)              | 1 (1.5)              | 1.000   |
| CMV+ infants at 12 months | 12/20 (60%)         | 25/35 (71.4%)        | 0.551   |

Values are expressed as median (IQR) or percentage
ART antiretroviral therapy, d4T stavudine, 3TC lamivudine, NVP nevirapine, AZT zidovudine
a Weight measured within the first 15 days of birth
b Infants acquiring HIV infection during the first year of life

Impact of EBV infection
At 24 months the 13 infants remaining EBV-seronegative did not differ from those who acquired the infection; no differences were found in male/female ratio, growing rate (BMI and malnutrition indices at different time points, data not shown), the occurrence of other infections. During the 24 months of follow-up, 67.8% of the infants experienced at least one of the most common infections reported in Malawi: gastroenteritis, respiratory infections, and malaria. Based on the timing of EBV infection acquisition, the prevalence of cumulative low respiratory tract infections (18.4.0%, 28.3 and 15.4%, p = 0.392), malaria (40.8, 43.4 and 69.2%, p = 0.175) and gastroenterological events (34.7, 34.0 and 53.8%, p = 0.925) did not differ between the infants that EBV-seroconverted at 12 months (n = 49), within 24 months (n = 53) and those remaining seronegative (n = 13) during the study.

The magnitude and the persistence of the immune response to HBV vaccination were measured in all infants by determining anti-HBs IgG titres. At 12 months anti-HBs concentrations did not differ in infants according to the presence of EBV infection (geometric mean EBV+: 101.7 ± 51.6 vs. EBV−: 138.4 ± 42.9 mIU/ml, p = 0.777). Anti-HBs IgG titres over 10 mIU/ml (considered protective) were observed in 87.2% of EBV+ and 92.2% of EBV− infants, p = 0.523.

At month 24 the anti-HBs titres were 124.8 ± 71.4 mIU/ml in EBV-seronegative infants, and 41.4 ± 45.4 mIU/ml and 49.4 ± 35.8 mIU/ml in infants who seroconverted at 12 months or at 24 months, respectively (intergroup difference p = 0.008, Fig. 1).

Generally, the longitudinal trend in anti-HBs IgG titres showed a decline in all infants which became statistically significant only in the EBV seropositive infants, independently by the time of seroconversion (EBV-free: p = 0.070; EBV+ month 12: p = 0.004, EBV+ month 24: p < 0.0001, Fig. 1). A more detailed description of the evolution of anti-HBs levels during 12–24 months is reported in Table 2. The proportion of infants with high (> 100 IU/ml) antibody levels is underrepresented (15/52, 28.8%) in infants that became infected during the second year of life, compared to infants with early infection (21/45, 46.7%) and EBV-negative infants (7/11, 63.6%). Importantly, more than 50% (27/52) of infants with EBV acquisition during the second year of life experienced a relevant decay of vaccine-specific anti-HBs Ab. At month
24, 82.7% of EBV-seropositive and 100% of EBV-seronegative infants had anti-HBs titres > 10 mIU/ml.

**Discussion**

In this study, we confirm that Epstein Barr Virus infection is common in early childhood in Malawi. In our cohort, EBV acquisition was not associated with the viro-immunological maternal conditions, while disadvantaged social conditions seemed to favor earlier EBV infection. EBV seroconversion did not seem to influence the infant’s growth and the vulnerability to other infections, but our data suggest that EBV infection could have an impact on the persistence of the immune response to HBV vaccination.

More than 90% of the global population in adult age is EBV-infected [24]. Here we report a 42.6% rate of EBV seroconversion in the first 12 months, rising to 88.7% of the total 115 HEU infants at 24 months. The rates and dynamics of EBV acquisition we found were comparable to data from previous studies (which found seroprevalences between 40 and 47% at 12 months), conducted in geographical regions (Kenya, Uganda, and Ghana) [25–27] that share analogous socioeconomic and environmental features of Malawi; similar dynamics of EBV infection has been observed even in the pre-HIV epidemic era [28], suggesting that HIV infection could have a marginal role in the early acquisition of EBV infection. In this view, we did not found any association between EBV seroconversion and maternal viro-immunological conditions.

EBV acquisition can occur in the first few months of life (1–6 months of age) when the maternal immunological conditions are severely compromised by infections such as malaria and HIV which can affect the placental transfer of adequate levels of protective antibodies [1, 25, 29–31]. In our study EBV seroconversion was not observed before 6 months; although only 52 infants were tested at 6 months of age, and no one had their own anti-VCA antibodies (in few cases they were of maternal origins, as

![Fig. 1](image-url)  
**Fig. 1** Longitudinal changes of anti-HBs IgG serum levels (geometric mean ± 5 SE) in the 12- and 24-months old infants: EBV seropositive infants to anti-VCA IgG from month 12 (n = 47, grey square); EBV seronegative at month 12 (n = 64) that seroconverted within month 24 (n = 51, white diamond) and those that remained anti-VCA IgG negative (n = 13, black circle)

| Month 12 | EBV + | EBV− | P values |
|----------|-------|------|---------|
| Number pz | n | 47 | 64 |
| Anti-HBs IgG (mIU/ml) | | 101.7 ± 51.8 | 138.4 ± 42.9 | 0.777 |
| Infants with anti-HBs > 10 mIU/ml (n, %) | 41 (87.2%) | 60 (92.2%) | 0.523 |

| Month 24 | EBV + at month 12 | EBV− at month 24 | EBV− |
|----------|-----------------|-----------------|------|
| Number pz | n | 45 | 52 | 11 |
| Anti-HBs IgG (mIU/ml) | | 41.4 ± 45.4 | 49.4 ± 35.8 | 128.4 ± 71.4 | 0.139 |
| Infants with anti-HBs > 10 mIU/ml (n, %) | 36 (78.3%) | 45 (86.5%) | 11 (100%) | 0.154 |

**Table 2** Longitudinal evolution of anti-HBs levels after HBV vaccination in infants that acquired EBV infection within 12 or 24 months or remained EBV negative

| Anti-HBs evolution over time | Maintenance or increase > 100 mIU/ml (n, %) | 21 (46.7%) | 15 (28.8%) | 7 (63.6%) | 0.039 |
|----------------------------|---------------------------------------------|-------------|-------------|---------|------|
| Stable levels > 10 < 100 mIU/ml (n, %) | 3 (6.7%) | 4 (7.7%) | 1 (9.1%) | | |
| Relevant decrease > 50 % (n, %) | 14 (31.0%) | 27 (51.9%) | 3 (27.3%) | | |
| Poor response < 10 mIU/ml (n, %) | 7 (15.6%) | 6 (11.5%) | 0 (0.0%) | | |

The persistency of anti-HBs titres was arbitrarily categorized into 4 types of dynamic responses to the vaccine.
confirmed by seronegative tests afterward), and including the other infants still seronegative at 12 months (66 out of 115), we are confident in saying that EBV infection was not acquired during the breastfeeding period. These findings are in agreement with previous studies [26, 33] reporting that the improved health maternal conditions (antenatal ART coverage and ART continuation in the breastfeeding period) may have an impact on the delayed onset of EBV infection.

A significant risk factor for EBV seroconversion in the first year of age was related to social disadvantages; although our study was not designed to examine direct markers of socioeconomic status, the mother’s educational level was a contributing factor for EBV seroconversion during the first years of life. Similar results have been observed by others [33, 34], highlighting that early EBV infection can vary globally from 20 to 80% depending on ethnic, geographical, and socioeconomic determinants [35].

Such as EBV infection, CMV infection typically occurs earlier in sub-Saharan Africa than in western countries [36]; in our study, 67.3% of infants acquired CMV infection during the first years of life. Many studies reported that the interactions between CMV and EBV co-infection can affect immune function and response to vaccination, both in children and adults [37–39]. In this study, we were not able to assess the possible synergic impact of CMV coinfection on humoral response, because of the limited number of infants with available CMV tests (n = 55).

In contrast with a recent study [27], we did not find a prevalence of abnormal growth in EBV-infected infants, and the EBV seroconversion was not associated with increased vulnerability to infections. However, we found interesting data on the immune response to HBV vaccination. As already observed, HEU infants are capable of mounting a sufficient immune response for HBV vaccination to confer adequate protection [14, 40]. In the present study, at month 12, a cumulative percentage of 90.1% of HEU infants had adequate anti-HBs IgG levels, which declined significantly at month 24, as already observed in a previous study on the same cohort [40]. Here we found that the EBV infection seems to influence the persistence of anti-HBs titres over time. At 12 months EBV-seronegative infants presented a 25% higher level of anti-HBs than their EBV-seropositive counterparts. Then, anti-HBs levels drastically declined in infants who EBV seroconverted in the following 12 months, while remained quite stable in the few infants that remained EBV-seronegative. The very limited number of infants belonging to the former group allows us only to speculate on the potential impact of EBV on functional responses of B-cells [41]. Pediatric studies reported reduced serological responses to vaccination to measles, rubella, and meningococcal polysaccharides (MPV) in EBV-positive children from different cohorts [7, 8] suggesting that the timing of EBV infection could affect the immunological response to vaccines by the rapid decay of adequate serological levels of protection. These data are consistent with EBV biology; the infection triggers important changes in the B cells by reprogramming biological processes, inducing mutations that may interfere with antibody production [5, 42].

This study has some important limitations. The limited number of infants and the high rate of EBV seroconversion in the first 2 years of life did not allow us to have sufficient statistical power to perform a more sophisticated analysis between EBV positive and negative children. Moreover, we have assumed positive anti-VCA IgG as the result of EBV infection and did not perform other serological tests nor confirmatory EBV-DNA determination, which could have allowed us to monitor the host control of EBV infection. However, anti-VCA antibodies levels remain relatively stable throughout the life of the host [30] and can be considered a good surrogate to detect EBV acquisition. Another limit of our study is the lack of information regarding laboratory-confirmed malaria (although our study took place in an endemic area for Plasmodium falciparum) since malaria is considered a strong predictor of early EBV primary infection [6, 31].

Conclusions

In conclusion, here we confirm that EBV acquisition in Malawian HEU infants occurs mostly during the first two years of life, and we suggest that the onset of infection can be delayed after 6 months of age, in the presence of improved immunological conditions of their HIV + ART-treated mothers. EBV acquisition does not seem to have an impact on children’s growth nor to increase their vulnerability to infections but infants with EBV acquisition have a reduced persistence of the immunological response to HBV vaccination, possibly compromising the long-term protection against hepatitis B infection. In this view, surveillance programs should be activated to monitor the serological persistency after vaccinations in areas endemic for early EBV infection, and possibly, re-schedule vaccination protocols, to confer lifelong adequate protection.

Abbreviations

HEU: HIV exposed uninfected; EBV: Epstein Barr Virus; ART: Antiretroviral treatment.

Acknowledgements

We are grateful to Alessandra Mattei and Stefania Donnini for helpful secretarial assistance, to Ferdinando Costa and Patrizia Cocco for technical assistance. We are grateful to all women and their infants who participated to this study.
Authors' contributions
SB and MG were responsible for the design of the study, and wrote the manuscript. SB was responsible for statistical analysis. CMG designed and supervised the laboratory procedures. GL and MA were responsible for data collection and management. RM, RL, and JBS, were responsible for the conduction of the study in Malawi. RA was involved in the laboratory assays. FC, SO and MCM participated in the design of the study and critically revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by a grant from the Ministry of Health, Rome, Italy (Grant No. 3C04/1).

Availability of data and materials
The data that support the findings of this study are available from the corresponding author, (SB), upon reasonable request.

Declarations

Ethics approval and consent to participate
Ethical approval was obtained from the National Health Research Committee in Malawi (approval number #486), and informed consent was obtained from all individual participants included in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 National Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. 2 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy. 3 Saint Camillus International University of Health Sciences, Rome, Italy. 4 DREAM Program, Community of S. Egidio, P.O. Box 30355, Blantyre, Malawi. 5 Department of Human Sciences, LUMSA University, Via Traspontina 21, 00193 Rome, Italy.

Received: 19 January 2021 Accepted: 28 July 2021
Published online: 04 August 2021

References
1. Pirillo E, Aisto AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, et al. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis. 2012;205(6):906–13.
2. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–93.
3. Baumforth, KR, Young LS, Flavell KG, Constantindou C, Murray PG. The Epstein-Barr virus and its association with human cancers. Mol Pathol. 1999;52(6):307–22.
4. Ayeje R, Ofonjo MEO, Wright E, Quaye O. Epstein Barr virus associated lymphomas and epithelia cancers in humans. J Cancer. 2020;11(7):1737–50.
5. Mrz-ek-Gorska P, Buschle A, Pich D, Schwarmazty T, Fechtner R, Scialdone A, et al. Epstein-Barr virus reprograms human B lymphocytes immediately in the prevalent phase of infection. Proc Natl Acad Sci USA. 2019;116(32):16046–55.
6. Chene A, Donat D, Orem J, Mbideke ER, Kironde F, Wubahgen M, et al. Endemic Burkitt’s lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol. 2009;19(6):411–20.
7. Holder B, Miles DJC, Kaye S, Crozier S, Mohammed NI, et al. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants. PLoS ONE. 2010;5(11):e14013.
8. Lasaviciute G, Bjorkander S, Carvalho-Queiroz C, Hed Myrberg I, Nussbaum B, Nilsson C, et al. Epstein-Barr virus, but not cytomegalovirus, latency accelerates the decay of childhood measles and rubella vaccine responses—a 10-year follow-up of a Swedish birth cohort. Front Immunol. 2017;8:1865.
9. Task Force for Global Hepatitis (TGFH). Coalition for Global Hepatitis Elimination (CGHE). 2019 Available at: https://www.globalhep.org/country-progress/malawi. Accessed July 2021.
10. Stockdale AJ, Mitambo C, Everett D, Geretti AM, Gordon MA. Epidemiology of hepatitis B, C and D in Malawi: systematic review. BMC Infect Dis. 2018;18:516.
11. WHO and UNICEF estimates of national immunization coverage. July 6, 2020; Available at: https://www.who.int/immunization/monitoring_surveillance/data/mwi.pdf. Accessed July 2021.
12. Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. HIV-exposed and uninfected, 2000–18: a modelling study. Lancet Glob Health. 2020;8:e67-75.
13. Slogrove AL, Esser MM, Cotton MF, Speert DP, Kollmann TR, Singer, J, et al. A Prospective cohort study of common childhood infections in South African HIV-exposed uninfected and HIV-unexposed infants. Pediatr Infect Dis J. 2017;36(2):e38-44.
14. Abu-Ray B, Kollmann TR, Marchant A, MacGillivray DM. The immune system of HIV-exposed uninfected infants. Front Immunol. 2016;7:383.
15. Brennan AT, Bonawitz R, Gift C, Thea D, Kleinman M, Useeen J, et al. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. AIDS. 2016;30(15):2351–60.
16. Giuliano M, Andreotti M, Liotta G, Jere H, Sagno JB, Maulidi M, et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS ONE. 2013;8(7):e68950.
17. World Health Organization. The Treatment of diarrhoea: a manual for physicians and other senior health workers. 4th rev. Geneva, Switzerland: World Health Organization; 2005. http://www.who.int/maternal_child_adolescent/documents/9241593180/en/ Accessed Nov 2020.
18. Zar HJ, Jeena P, Argent A, Gre R, Madhi SA. Working Groups of the Paediatric Assembly of the South African Thoracic Society Diagnosis and management of community-acquired pneumonia in childhood—South African Thoracic Society guidelines. South Afr J Epidemiol Infect. 2009;24(12 pt):25–36.
19. Pinillo MF, Liotta G, Andreotti M, Jere H, Sagno JB, Scarcella P, et al. CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. Med Microbiol Immunol. 2017;206(1):23.
20. Das S, et al. Hepatitis B vaccine and immunoglobulin: key concepts. J Cln Transl Hepatol. 2019;7(2):165–71.
21. Gibbon RS. Principles of nutritional assessment. New York: Oxford University Press, 2005.
22. WHO. United Nations Children’s Fund: WHO child growth Standards and the identification of severe acute malnutrition in infants and children. A Joint Statement 2009 At: http://www.who.int/nutrition/publications/severemalnutrition/9789241598163/en/ Accessed Nov 2020.
23. WHO Child Growth Standards: methods and development Length/ height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age. Geneva: World Health Organization. 2006.
24. Gocci L, Winter JP, Taylor GS, Lewis, JEA, Stagg HR. Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy. Sci Rep. 2019;9(1):2920.
25. Slyker JA, Casper C, Tapia K, Richardson B, Bunts L, Huang ML, et al. Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women. J Infect Dis. 2015;212(7):178–806.
26. Gant S, Orem J, Krantz EM, Morrow RA, Selke S, Huang ML, et al. Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants. J Infect Dis. 2016;214(1):36–44.
27. Montoya-Fener A, Sanoysan A, Fay'dherbe De Maudave A, Pisoni A, Boldor K, Molés JP, et al. Clinical and biological factors associated with early Epstein-Barr virus infection in HIV-exposed uninfected infants in Eastern Uganda. Clin Infect Dis. 2020;18:ciaa161.
28. Biggar RJ, Henle W, Fleisher G, Böcker J, Henle G. Primary Epstein-Barr virus infections in African infants: I. Decline of maternal antibodies and time of infection. Int J Cancer. 1978;22(3):239–43.
29. Daud I, Coleman CB, Smith NA, Ogolla S, Simbiri K, Bukusi EA, et al. Breast milk as a potential source of Epstein-Barr virus transmission among infants living in a malaria-endemic region of Kenya. J Infect Dis. 2015;212(11):1735–42.
30. Reynaldi A, Schlub TE, Piriou E, Ogolla S, Sumba OP, Moormann AM, et al. Modeling of EBV infection and antibody responses in Kenyan infants with different levels of malaria exposure shows maternal antibody decay is a major determinant of early EBV infection. J Infect Dis. 2016;214(9):1390–8.
31. Ogolla S, Daud I, Asito AS, Sumba OP, Ouma C, Vulule J, et al. Reduced transplacental transfer of a subset of Epstein-Barr Virus-specific antibodies to neonates of mothers infected with Plasmodium falciparum malaria during pregnancy. Clin Vaccine Immunol. 2015;22(11):1197–205.
32. Ruck C, Reikie BA, Marchant A, Collmann TR, Kakkar F. Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. Front Immunol. 2016;7:757.
33. Minhas V, Brayfield BP, Crabtree KL, Kankasa C, Mitchell CD, Wood C. Primary gamma-herpesviral infection in Zambian children. BMC Infect Dis. 2010;10:115.
34. Gates V, Panico L, Castagne R, Delpierre C. And On behalf of the Lifepath consortium. The role of the early social environment on Epstein Barr virus infection: a prospective observational design using the Millennium Cohort Study. Epidemiol Infect. 2016;145(16):3405–3412.
35. Schmeer KK, Ford JL, Browning CR. Early childhood family instability and immune system dysregulation in adolescence: Psychoneuroendocrinology. 2019;102:189–95.
36. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–13.
37. Saghaftian-Hedengren S, Sundstrom Y, Sohberg E, Nilsson C, Linde A, et al. Herpesvirus seropositivity in childhood associates with decreased monocyte-induced NK cell IFN-gamma production. J Immunol. 2009;182:2511–7.
38. Gumbo H, Chasekwa B, Church JA, Ntozini R, Mutasa K, Humphrey JH, Prendergast AJ. Congenital and postnatal CMV and EBV acquisition in HIV-infected Zimbabwean infants. PLoS ONE. 2014;9(12):e114870.
39. Merani S, Pawelec G, Kuchel GA, McElhaney JE. Impact of aging and cytomegalovirus on immunological response to influenza vaccination and infection. Front Immunol. 2017;8:784.
40. Mancinelli S, Pirillo MF, Liotta G, Andreotti M, Mphwere R, Amici R, et al. Antibody response to hepatitis B vaccine in HIV-exposed infants in Malawi and correlation with HBV infection acquisition. J Med Virol. 2018;90(6):1172–6.
41. Wang C, Liu Y, Xu L, Jackson K, Roskin K, Pham T, et al. Effects of aging, CMV infection, and EBV infection on human B cell repertoires. J Immunol. 2014;192(2):603.
42. Souza T, Stollar B, Sullivan J, Luzuriaga K, Thorley-Lawson D. Influence of EBV on the peripheral blood memory B cell compartment. J Immunol. 2007;179(50):3153–60.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions